Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma

Human Pathology

Volumn 39, Issue 8, 2008, Pages 1239-1251

  Gilks, C Blake ^a   Ionescu, Diana N ^a   Kalloger, Steve E ^a   Köbel, Martin ^a,b   Irving, Julie ^a   Clarke, Blaise ^a   Santos, Jennifer ^c   Le, Nhu ^c   Moravan, Veronika ^c   Swenerton, Kenneth ^c  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Cell type; Grade; Ovarian cancer; Prognosis

Indexed keywords

ARTICLE; CANCER GRADING; CANCER STAGING; CELL TYPE; CLEAR CELL CARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; KAPPA STATISTICS; MUCINOUS CARCINOMA; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVARY CARCINOMA; PATHOLOGIST; PROGNOSIS; RELAPSE; REPRODUCIBILITY; STATISTICAL SIGNIFICANCE; SURVIVAL; TUMOR CELL; TUMOR CLASSIFICATION;

AGED; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OBSERVER VARIATION; OVARIAN NEOPLASMS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; WT1 PROTEINS;

EID: 47749086997     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.01.003     Document Type: Article

References (43)

1. Cannistra S.A. Cancer of the ovary. N Engl J Med 351 (2004) 2519-2529
2. Silverberg S.G., Bell D.A., Kurman R.J., et al. Borderline ovarian tumors: key points and workshop summary. Hum Pathol 35 (2004) 910-917
3. Zaloudek C. "Tumors of the ovary". In: Fletcher C.D.M. (Ed). Diagnostic Histopathology of Tumors (2000), Churchill Livingstone, London 567-642
4. Shaw P.A., McLaughlin J.R., Zweemer R.P., et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 21 (2002) 407-411
5. Shih I., and Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164 (2004) 1511-1518
6. Itamochi K., Kigawa J., Sugimoya T., et al. Low proliferative activity my be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100 (2002) 281-287
7. Sugiyama T., Kamura T., Kigawa J., et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic cell type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88 (2000) 2584-2589
8. Schwartz D.R., Kardia S.L., Shedden K.A., et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62 (2002) 4722-4729
9. Risch H.A., McLaughlin J.R., Cole D.E., et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68 (2001) 700-710
10. Trimble E.L., Fountain J., and Birrer M.J. Recommendations of the 2005 Ovarian Cancer State of the Science Meeting. Gynecol Oncol 103 (2006) S26
11. Silverberg S.G. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19 (2000) 7-15
12. Shimizu Y., Kamoi S., Amada S., Akiyama F., and Silverberg S.G. Toward the development of an universal grading system for ovarial epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82 (1998) 893-901
13. Shimizu Y., Kamoi S., Amada S., Hasumi K., Akiyama F., and Silverberg S.G. Toward the development of a universal grading system for ovarian epithelial carcinoma: I. Prognostic significance of histopathologic features-problems involved in the architectural grading system. Gynecol Oncol 70 (1998) 2-12
14. Malpica A., Deavers M.T., Lu K., et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28 (2004) 496-504
15. Singer G., Shih Ie M., Truskinovsky A., Umudum H., and Kurman R.J. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol 22 (2003) 37-41
16. Singer G., Kurman R.J., Chang H.W., Cho S.K., and Shih Ie M. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160 (2002) 1223-1228
17. Singer G., Oldt III R., Cohen Y., et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95 (2003) 484-486
18. Singer G., Stohr R., Cope L., et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis. Am J Surg Pathol 29 (2005) 218-224
19. Piccart M.J., Bertelsen K., James K., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three year results. J Natl Cancer Inst 92 (2000) 699-708
20. International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 50 (1971) 1-7
21. In: Tavassoli F.A., and Devilee P. (Eds). World Health Organization classification of tumours: Pathology and genetics. Tumours of the breast and female genital organs (2003), IARC Press, Lyon, France
22. Parker R.L., Huntsman D.G., Lesack D.W., et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 117 (2002) 723-728
23. Gilks C.B. Subclassification of ovarian surface epithelial carcinomas based on correlation of histological and molecular pathologic data. Int J Gynecol Pathol 23 (2004) 200-205
24. Palacios J., and Gamallo C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 58 (1998) 1344-1347
25. Wu R., Zhai Y., Fearon E.R., and Cho K.R. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 61 (2001) 8247-8255
26. Cuatecasas M., Villaneuva A., Matias-Guiu X., and Prat J. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 79 (1997) 1581-1586
27. Havrilesky L., Darcy K.M., Hamdan H., et al. Prognostic significance of p53 overexpression and mutation in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3814-3825
28. Katabuchi H., Tashiro H., Cho K.R., Kurman R.J., and Hedrick E.L. Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53. Int J Gynecol Pathol 17 (1998) 54-60
29. Geisler J.P., Hatterman-Zogg M.A., Rathe J.A., and Buller R.E. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 94 (2002) 61-67
30. Hilton J.L., Geisler J.P., Rathe J.A., Hattermann-Zogg M.A., DeYoung B., and Buller R.E. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 94 (2002) 1396-1406
31. Crispens M.A., Bodurka D., Deavers M., Lu K., Silva E.G., and Gershenson D.M. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 99 (2002) 3-10
32. Gershenson D.M., Sun C.C., Lu K.H., et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108 (2006) 361-368
33. Hernandez E., Bhagavan B.S., Parmeley T.H., and Rosenshein N.B. Interobserver variability in the interpretation of epithelial ovarian cancer. Gynecol Oncol 17 (1984) 117-123
34. Cramer S.F., Roth L.M., Ulbright T.M., et al. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. Arch Pathol Lab Med 111 (1987) 819-829
35. Lund B., Thomsen H.K., and Olsen J. Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. APMIS 99 (1991) 353-358
36. Sakamoto A., Sasaki H., Furusato M., et al. Observer disagreement in histological classification of ovarian tumors in Japan. Gynecol Oncol 54 (1994) 54-58
37. Al-Hussaini M., Stockman A., Foster H., and McCluggage W.G. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 46 (2005) 468
38. Kobel M., Langhammer T., Huttelmaier S., et al. Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. Mod Pathol 19 (2006) 581-587
39. Alkushi A., Abdul-Rahman Z.H., Lim P., Schulzer M., Coldman A., Kalloger S.E., Miller D., and Gilks C.B. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol. 29 (2005) 295-304
40. Ishioka S., Sagae S., Terasawa K., Sugimura M., Nishioka Y., Tsukada K., and Kudo R. Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system. Gynecol Oncol 89 (2003) 447-452
41. Mayr D., and Diebold J. Grading of ovarian carcinomas. Int J Gynecol Pathol 19 (2000) 348-353
42. Sato Y., Shimamoto T., Amada S., Asada Y., and Hayashi T. Prognostic value of histologic grading of ovarian carcinomas. Int J Gynecol Pathol 22 (2003) 52-56
43. Malpica A., Deavers M.T., Tomos C., et al. Inter-observer and intra-observer variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 31 (2007) 1203-1208